J. Safra Sarasin Holding AG Takes $2.23 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

J. Safra Sarasin Holding AG purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,125 shares of the biopharmaceutical company's stock, valued at approximately $2,226,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $802,036,000. Amundi increased its position in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after purchasing an additional 393,997 shares during the period. Finally, Proficio Capital Partners LLC boosted its holdings in Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after purchasing an additional 219,162 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.5 %

NASDAQ:REGN traded up $2.88 during mid-day trading on Friday, hitting $602.64. The stock had a trading volume of 964,377 shares, compared to its average volume of 723,778. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The stock has a 50-day simple moving average of $637.38 and a two-hundred day simple moving average of $725.82. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $65.88 billion, a PE ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $11.86 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating on the stock in a research report on Wednesday. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $945.32.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.